Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
A dedicated diabetes NDA filing is expected to follow the obesity NDA
34 The AHA guidelines endorse GLP-1 RAs, including semaglutide and liraglutide, because these medications have shown significant benefits in reducing major adverse cardiovascular events (MACE) and heart failure exacerbations, as demonstrated in the LEADER and SUSTAIN-6 trials (Table 3)
Meet our doctors Last reviewed: 19 Jun 2026 Sources Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients (2020) NIH [accessed 27 January 2026] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (2023) The Lancet [accessed 27 January 2026] How to use Mounjaro (2023) Mounjaro [accessed 27 January 2026] Lillys SURMONT-2 results published in The Lancet show tirzepatide achieve a mean weight reduction of 15.7% at the highest dose (15mg) in adults with obesity or overweight and type 2 diabetes (2023) Lillys INVESTORS [accessed 27 January 2026] MHRA authorised diabetes drug Mounjaro (tirzepatide) for weight management and weight loss (2023) GOV.UK
Suppressing appetite: Many patients experience a reduced desire to eat, supporting weight management goals
In addition, they promote feelings of fullness, making them a valuable tool for weight management
